TORONTO, March 2, 2016 /CNW/ - Bedrocan Canada, wholly-owned subsidiary of Canopy Growth Corporation (Canopy Growth) (TSXV:CGC) today continued its commitment to affordable medical cannabis treatment by offering vaporizers at cost. The offer, available to all registered Bedrocan Canada clients, is a part of a wider effort to reduce the cost of medicating with cannabis.
"Bedrocan is fully engaged with the medical community and respects the concern many physicians have with inhaling burnt plant matter as a means to medicate," said Marc Wayne, Bedrocan Canada's President. "Offering deep discounts on vaporizers is a way to address this concern by making alternative therapy applications more affordable."
Bedrocan Canada already offers the most affordable full line of standardized cannabis varieties in the country. Via True Compassionate Pricing, all Bedrocan varieties cost $5 per gram for all registered clients.
"Bedrocan Canada is and will always be a medical cannabis company," said Bruce Linton, CEO of Canopy Growth. "Canada's cannabis laws are evolving but Bedrocan Canada is focused on advancements on the medical side of the industry. By advocating for tax amendments, coordinating research initiatives and facilitating physician education, the team at Bedrocan Canada remains focused on its core business."
To learn more about Bedrocan Canada's vaporizer selection and pricing, visit www.bedrocan.ca
About Bedrocan Canada
Bedrocan Canada is focused on medicinal cannabis production and research, including, the EQUAL Study, which is currently enrolling patients and evaluating how cannabis is affecting their quality of life of Canadian patients. Bedrocan's standardized strains have been used by tens of thousands of patients in seven countries around the world. www.bedrocan.ca
About Canopy Growth Corporation
Canopy Growth is Canada's first publicly traded medical marijuana company and the first geographically diversified producer with multiple licenses under the Marihuana for Medical Purposes Regulations. Through its wholly owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, the Company operates three state-of-the-art production facilities in Ontario and distributes marijuana across the country to Canadian patients managing a host of medical conditions. The Company is dedicated to educating healthcare practitioners, providing consistent access to high quality medication, conducting robust clinical research, and furthering the public's understanding of how marijuana is used for medical purposes. www.canopygrowth.com
Forward Looking Statement:
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or any of its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Although Canopy Growth Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The factors identified above are not intended to represent a complete list of the factors that could affect the Company or any of its subsidiaries. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Canopy Growth Corporation
For further information: Media Contact: Jordan Sinclair, Jordan@canopygrowth.com, 855-558-9333 ex 309; Investor Contact: Tyler Burns, Tyler.email@example.com, 855-558-9333 ex 122; Director: Bruce Linton, firstname.lastname@example.org